Company intelligence / Profile preview
AbGenomics
San Francisco Bay Area, California, United Statesabgenomics.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
AbGenomics’ lead candidate neihulizumab targets PSGL‑1 and has reached Phase 2 for autoimmune indications such as type 1 diabetes and psoriasis. The company has demonstrated safety and biological activity in early clinical trials. Additional programs are in preclinical development for oncology and immune-related diseases[2][5].
- Therapeutic areas
- DermatologyGastroenterologyEndocrinologyOncologyImmunology
- Modalities
- Antibody-drug conjugateMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborates with major pharmaceutical partners for commercialization strategy
Beyond the preview
Go deeper on AbGenomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbGenomics.